Efficacy, Immunogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants

The purpose of this study is to assess the efficacy, immunogenicity and safety of GSK Biologicals' liquid human rotavirus vaccine in healthy Chinese infants 6 to 16 weeks of age.

本研究旨在评估葛兰素史克生物制品（GSK Biologicals）生产的液态人轮状病毒疫苗，在6至16周龄健康中国婴儿中的效力、免疫原性与安全性。